Early therapy in active rheumatoid arthritis Akti̇f romatoi̇d artri̇tte erken tedavi̇

Bilgici A., Kuru Ö.

Journal of Rheumatology and Medical Rehabilitation, cilt.14, sa.1, ss.37-47, 2003 (Scopus) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 14 Sayı: 1
  • Basım Tarihi: 2003
  • Dergi Adı: Journal of Rheumatology and Medical Rehabilitation
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.37-47
  • Anahtar Kelimeler: Drug therapy, Drug toxicity, Early rheumatoid artritis, Rheumatoid artritis
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Arresting and preventing structural damage is a primary goal of therapy in rheumatoid arthritis(RA). The current trent in the treatment of RA is to intervene early, before the development of irreversible joint damage. The majority of patients with newly diagnosed RA should be started on disease-modifying antirheumatic drug (DMARD) therapy within 3 months of diagnosis. Each DMARD has specific toxicity that requires careful monitoring. Therefore, physician who care for these patients need to be aware of the potential adverse effects of these medications. The physician should also assess many factors such as compliance of patient, the severity and prognosis of the disease, and the physician's own confidence in administering the drug for the decision regarding the initiation and selection of a DMARD.